Use of a nutritional composition

Abstract

The present invention relates to the use of a nutritional composition, more particularly to the use of a nutritional composition in the manufacture of a product for improving intestinal colic and / or abdominal distension, wherein the nutritional composition comprises partially hydrolyzed protein and docosahexaenoic acid (DHA). The partially hydrolyzed protein and the docosahexaenoic acid, when used in combination, are capable of synergistically improving intestinal colic and / or abdominal distension.

Description

Technical Field

[0001] This disclosure relates to the use of nutritional compositions in the preparation of products for improving intestinal colic and / or bloating. Background Technology

[0002] Colic and bloating are common and uncomfortable gastrointestinal symptoms with a high incidence in both infants and adults, significantly impacting individual health and quality of life.

[0003] Infant colic is a common symptom that is prevalent in infancy, but its etiology is not fully understood. Statistics show that approximately 5% to 25% of infants suffer from colic [Ying Liping, Mao Huiying. Infant crying may be due to colic [J]. Health Expo, 2025, (05): 54]. Its main clinical manifestations are paroxysmal, inconsolable, and intense crying, each episode lasting an hour or longer, often accompanied by abdominal distension, abdominal wall tension, flexed legs, and other signs of abdominal discomfort, and may also include increased flatulence and vomiting [Ying Liping, Mao Huiying. Infant crying may be due to colic [J]. Health Expo, 2025, (05): 54; Jia Yang. Methods to relieve neonatal colic [J]. Mama & Baby, 2025, (01): 56-57]. This not only causes suffering for infants but also places enormous emotional stress and care burden on caregivers. Therefore, developing methods and products that can effectively reduce or prevent infantile colic is of great clinical and social significance.

[0004] In adults, lower gastrointestinal symptoms such as bloating and flatulence are also common. Stress from modern lifestyles, especially chronic stress, has been proven to be closely related to the occurrence and exacerbation of functional gastrointestinal disorders such as irritable bowel syndrome (IBS). Studies show that over 50% of the general population has reported experiencing gastrointestinal discomfort symptoms, with bloating and flatulence being the most common [Whitehead WE, et al. Stressful life events and their impact on bowelsymptoms: A comparison of subjects with irritable bowel syndrome to those without bowel dysfunction]. This indicates that gastrointestinal dysfunction and associated bloating are a widespread health problem in adults.

[0005] Currently, there are various management strategies for the above symptoms, including behavioral interventions and drug relief, but these often have limitations. For example, medication use in infants and young children requires special caution, and long-term medication use in adults may be accompanied by side effects or adherence problems. Therefore, it is particularly important to seek a safer, more convenient, and easier-to-adhere-to-long-term intervention approach.

[0006] Therefore, it is of great significance to develop a method to improve intestinal colic and / or bloating. Summary of the Invention

[0007] This invention was made in view of the above-mentioned problems existing in the prior art.

[0008] This invention relates to the use of a nutritional composition in the preparation of a product for improving intestinal colic and / or bloating, wherein the nutritional composition comprises partially hydrolyzed protein and docosahexaenoic acid (DHA).

[0009] The inventors unexpectedly discovered during their research that partially hydrolyzed protein and docosahexaenoic acid (DHA) can synergistically improve colic and bloating when used in combination. Attached Figure Description

[0010] Figure 1 This is a typical image of zebrafish behavior after sample treatment. The black line represents the distance traveled at slow speed, the green line at medium speed, and the red line at fast speed.

[0011] Figure 2 This is a graph showing the measurement of the intestinal lumen area of ​​zebrafish after sample processing. Detailed Implementation

[0012] The following definitions are provided to enable those skilled in the art to understand the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Preferred materials and methods are described herein, but any methods and materials similar to or equivalent to those described herein may be used in the practice of testing the invention. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0013] Unless otherwise indicated or defined, all terms used have their ordinary meaning in the art as would be understood by those skilled in the art. Furthermore, unless otherwise stated, all methods, steps, techniques, and operations not specifically detailed herein may be performed and have been carried out in a manner known per se as would be understood by those skilled in the art.

[0014] This invention relates to the use of a nutritional composition in the preparation of a product for improving intestinal colic and / or bloating, wherein the nutritional composition comprises partially hydrolyzed protein and docosahexaenoic acid (DHA).

[0015] The applicant found that when the nutritional composition contains partially hydrolyzed protein and docosahexaenoic acid (DHA), the two can synergistically improve colic and bloating.

[0016] As used herein, the term "partially hydrolyzed protein" refers to a product obtained by partially hydrolyzing a protein to a lesser degree than complete hydrolysis. The partially hydrolyzed protein may comprise a mixture of protein fragments, polypeptides, peptides, amino acids, and / or peptones. It should be understood that partial hydrolysis does not include products obtained from complete hydrolysis of a protein consisting solely of free amino acids.

[0017] The hydrolysis process can be, for example, acid hydrolysis, alkaline hydrolysis, and / or enzymatic hydrolysis, with enzymatic hydrolysis being preferred. Unbound by any theory, enzymatic hydrolysis exhibits higher selectivity at cleavage sites on protein molecules compared to acid or alkaline hydrolysis, thereby yielding protein fragments and peptides with more controllable molecular weight distribution and more stable functional properties. Generally, acid hydrolysis tends to produce smaller molecular weight fragments, alkaline hydrolysis tends to produce larger molecular weight fragments, while enzymatic hydrolysis typically produces medium molecular weight fragments in between.

[0018] The partially hydrolyzed protein may be a partially hydrolyzed animal protein and / or a partially hydrolyzed plant protein. In some embodiments, the partially hydrolyzed protein is a partially hydrolyzed plant protein, selected from one or more of soy protein, pea protein, wheat protein, and rice protein. In some embodiments, the partially hydrolyzed protein is a partially hydrolyzed animal protein, such as partially hydrolyzed milk protein (i.e., partially hydrolyzed cow's milk protein), selected from whey protein, casein, or mixtures thereof, preferably whey protein.

[0019] In some embodiments, the degree of hydrolysis of the partially hydrolyzed protein may be 7% to 25%; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. The degree of hydrolysis of the partially hydrolyzed protein may be, for example, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, or within the range defined by any two of these. Preferably, the degree of hydrolysis of the partially hydrolyzed protein is 10%-25%; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0020] In some embodiments, peptides with a molecular weight >5000 Da account for 10%-80% of the mass of the partially hydrolyzed protein; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. In the partially hydrolyzed protein, the proportion of peptides with a molecular weight >5000 Da is, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight >5000 Da account for 10%-70% by mass, within which the nutritional composition has a more significant effect on improving intestinal colic and / or bloating; preferably, in the partially hydrolyzed protein, peptides with a molecular weight >5000 Da account for 10%-35% by mass, within which the nutritional composition has a more significant effect on improving intestinal colic and / or bloating.

[0021] In some embodiments, the proportion of peptides with a molecular weight of 1000-5000 Da in the partially hydrolyzed protein is 7%-47% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. The proportion of peptides with a molecular weight of 1000-5000 Da in the partially hydrolyzed protein is, for example, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight of 1000-5000 Da account for 10%-35% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0022] In some embodiments, peptides with a molecular weight <1000 Da account for 13%-80% of the mass of the partially hydrolyzed protein; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating. In the partially hydrolyzed protein, the proportion of peptides with a molecular weight <1000 Da is, for example, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, or within the range defined by any two of these. Preferably, in the partially hydrolyzed protein, peptides with a molecular weight <1000 Da account for 25%-78% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating.

[0023] In some preferred embodiments, the degree of hydrolysis of the partially hydrolyzed protein is 10%-25%, the proportion of peptides with a molecular weight >5000 Da is 10%-35% by mass, the proportion of peptides with a molecular weight of 1000-5000 Da is 10%-35% by mass, and the proportion of peptides with a molecular weight <1000 Da is 25%-78% by mass; within this range, the nutritional composition is more effective in improving intestinal colic and / or bloating, especially intestinal colic.

[0024] The partially hydrolyzed protein may be a single partially hydrolyzed protein or a mixture of two or more partially hydrolyzed proteins.

[0025] In some embodiments, the mass ratio of the partially hydrolyzed protein to docosahexaenoic acid in the nutritional composition is (5-719):1, for example, 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 105:1, 110:1, 115:1, 120:1, 125:1, 130:1, 135:1, 140:1, 145:1, 150:1, 155:1, 160:1, 165:1, 170:1, 175:1. 1, 180:1, 185:1, 190:1, 195:1, 200:1, 205:1, 210:1, 215:1, 220:1, 225:1, 230:1, 235:1, 240:1, 245:1, 250:1, 255:1, 260:1, 265:1, 270:1, 275:1, 280:1, 285:1, 290:1, 295:1, 300:1, 305:1, 310:1, 315:1, 320:1, 325:1, 330:1, 335:1, 340:1, 345:1, 350:1, 355:1, 360:1, 365:1, 370:1, 375 :1, 380:1, 385:1, 390:1, 395:1, 400:1, 405:1, 410:1, 415:1, 420:1, 425:1, 430:1, 435:1, 440:1, 445:1, 450:1, 455:1, 460:1, 465:1, 470:1, 475:1, 480:1, 485:1, 490:1, 495:1, 500:1, 505:1, 510:1, 515:1, 520:1, 525:1, 530:1, 535:1, 540:1, 545:1, 550:1, 555:1, 560:1, 565:1, 570:1, 5 The ratios are 75:1, 580:1, 585:1, 590:1, 595:1, 600:1, 605:1, 610:1, 615:1, 620:1, 625:1, 630:1, 635:1, 640:1, 645:1, 650:1, 655:1, 660:1, 665:1, 670:1, 675:1, 680:1, 685:1, 690:1, 695:1, 700:1, 705:1, 710:1, 715:1, 719:1, or within the range defined by any two of them; within this range, the synergistic effect of the partially hydrolyzed protein and docosahexaenoic acid in improving intestinal colic and bloating is more pronounced.

[0026] In some embodiments, the mass ratio of the partially hydrolyzed protein to docosahexaenoic acid in the nutritional composition is (5-180):1; within this range, the synergistic effect of the partially hydrolyzed protein and docosahexaenoic acid in improving intestinal colic is more significant.

[0027] In some embodiments, the mass ratio of the partially hydrolyzed protein to docosahexaenoic acid in the nutritional composition is (5-15):1; within this range, the synergistic effect of the partially hydrolyzed protein and docosahexaenoic acid in improving intestinal colic is more significant.

[0028] In some embodiments, the mass ratio of the partially hydrolyzed protein to docosahexaenoic acid in the nutritional composition is (15-180):1; within this range, the synergistic effect of the partially hydrolyzed protein and docosahexaenoic acid in improving bloating is more significant.

[0029] In some embodiments, the product is used to relieve intestinal colic. In some embodiments, the product is used to relieve bloating. In some embodiments, the product is used to relieve both intestinal colic and bloating.

[0030] In some embodiments, the product is a drug.

[0031] In some embodiments, the content of the partially hydrolyzed protein in the product is 0.1% to 20% based on the total dry weight of the product, for example, within the range defined by 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, or any two of these.

[0032] In some embodiments, the content of docosahexaenoic acid in the product is 0.01% to 0.5% based on the total dry weight of the product, for example, within the range defined by 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, or any two of these.

[0033] In some embodiments, the drug may be any dosage form, such as a solid dosage form (granules, powders, tablets, etc.) or a liquid dosage form. Furthermore, those skilled in the art will readily understand that, depending on the dosage form and application scenario, the drug may also include various pharmaceutically permissible excipients.

[0034] The products, such as pharmaceuticals, can be prepared using methods commonly employed in the art, which will not be elaborated upon here.

[0035] In some embodiments, when taken orally in humans, the dose of the partially hydrolyzed protein is 1-75 g / day, for example, 1 g / day, 2 g / day, 3 g / day, 4 g / day, 5 g / day, 6 g / day, 7 g / day, 8 g / day, 9 g / day, 10 g / day, 11 g / day, 12 g / day, 13 g / day, 14 g / day, 15 g / day, 16 g / day, 17 g / day, 18 g / day, 19 g / day, 20 g / day, 21 g / day, 22 g / day, 23 g / day, 24 g / day, 25 g / day, 26 g / day, 27 g / day, 28 g / day, 29 g / day, 30 g / day, 31 g / day, 32 g / day, 33 g / day, 34 g / day, 35 g / day, 36 g / day, 37 g / day, 38 g / day, 38 g / day, 38 g / day, 39 g / day, 30 g / day, 31 g / day, 32 g / day, 33 g / day, 34 g / day, 35 g / day, 36 g / day, 37 ... g / d, 39 g / d, 40 g / d, 41 g / d, 42 g / d, 43 g / d, 44 g / d, 45 g / d, 46 g / d, 47 g / d, 48 g / d, 49 g / d, 50 g / d, 51 g / d, 52 g / d, 53 g / d, 54 g / d, 55 g / d, 56 g / d, 57 g / d, 58 g / d, 59 g / d, 60 g / d, 61 g / d, 62 g / d, 63 g / d, 64 g / d, 65 g / d, 66 g / d, 67 g / d, 68 g / d, 69 g / d, 70 g / d, 71 g / d, 72 g / d, 73 g / d, 74 g / d, 75 g / d, or within the range defined by any two of them.

[0036] In some embodiments, when taken orally in humans, the dosage of DHA is 0.03-1.5 g / day, for example, 0.03 g / day, 0.06 g / day, 0.09 g / day, 0.12 g / day, 0.15 g / day, 0.18 g / day, 0.21 g / day, 0.24 g / day, 0.27 g / day, 0.30 g / day, 1 g / day, 1.5 g / day, or any two of these ranges.

[0037] In some implementations, there are no particular limitations on the subjects for improving intestinal colic and / or bloating, and may include, for example, infants, toddlers, children, adolescents, adults, young adults, middle-aged people, and / or the elderly.

[0038] As used herein, the following terms have the following meanings.

[0039] The term "infant" refers to a person from birth to 12 months of age.

[0040] The term "infant" refers to a person aged 1 - 3 years.

[0041] The term "child" refers to a person aged 3 - 7 years.

[0042] The term "adolescent" refers to a person aged 7 - 17 years.

[0043] The term "adult" refers to a person aged 18 years or older.

[0044] The term "young adult" refers to a person aged 18 - 40 years.

[0045] The term "middle - aged person" refers to a person aged 41 - 65 years.

[0046] The term "elderly person" or "senior citizen" refers to a person aged 65 years or older.

[0047] Examples

[0048] The present invention will be more easily understood by referring to the following examples, which are only used to illustrate some aspects and embodiments of the present invention and are not intended to limit the present invention.

[0049] Unless otherwise specified, the materials used in this embodiment are all commercially available materials or conventional materials.

[0050] Experimental animals

[0051] Zebrafish were all reared in fish - raising water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450 - 550 μS / cm; pH was 6.5 - 8.5; hardness was 50 - 100 mg / L CaCO3). They were provided by the fish - raising center of our company, and the license number for the use of experimental animals was: SYXK(Zhe)2022 - 0004. The feeding management met the requirements of international AAALAC accreditation (accreditation number: 001458), and the IACUC ethical review number was: IACUC - 2025 - 10307 - 01.

[0052] Instruments, consumables and reagents

[0053] Dissecting microscope (SZX7, OLYMPUS, Japan);

[0054] Zebrafish behavior analysis system (Zebra Lab 3.22.3.31, Viewpoint, France);

[0055] 150 mm * 25 mm culture dish (Orange Scientific, Belgium);

[0056] 96-well plate (Nest Biotech, China);

[0057] Trinitrobenzenesulfonic acid (TNBS, lot number 1003429412, Sigma, USA);

[0058] Dimethyl sulfoxide (DMSO, lot number BCCD8942, Sigma, Switzerland);

[0059] Partially hydrolyzed protein is sourced from FrieslandCampina (10%-25% degree of hydrolysis, produced in Firesland, product name Hyvital® Whey EtD 100);

[0060] Docosahexaenoic acid (DHA) was purchased from Noah Saint-Noah, with a purity of 22%, product specification 50905-020, and batch number 241111307201.

[0061] Prednisolone, white powder, batch number B1823016, purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., stored at 4°C, solvent is DMSO.

[0062] In the following examples, the amounts and ratios of each component are based on the amount of the corresponding active ingredient. For example, for DHA, the amount is based on the amount of pure DHA contained in the DHA raw material; for partially hydrolyzed protein, the amount is based on the protein content in the partially hydrolyzed protein raw material.

[0063] Determination of the maximum detectable concentration (MTC) of a sample used in an experiment evaluating the efficacy of a single-component treatment for improving colic and bloating.

[0064] Wild-type AB strain zebrafish, 3 days post-fertilization (3 dpf), were randomly selected and placed in culture dishes. Except for the normal control group, all experimental groups were treated with TNBS dissolved in water to establish a zebrafish colic model. After treatment at 28℃ for 2 days, the TNBS was removed and the zebrafish were distributed to 6-well plates, with 30 zebrafish treated in each well (experimental group). The samples were then dissolved in water (concentrations shown in Table 1), and a normal control group and a model control group were also included, with a volume of 3 mL per well. After another 2 days of treatment at 28℃, the number of zebrafish deaths and toxicity were recorded in each experimental group to determine the MTC of the samples in the model zebrafish.

[0065] Following the above method, zebrafish were administered partially hydrolyzed protein and docosahexaenoic acid at different dosages to determine the maximum detectable concentration (MTC) of the sample for evaluating the efficacy of the single-component treatment in improving intestinal colic and bloating. The dosages and results are shown in Table 1.

[0066] Table 1. Determination of the maximum detectable concentration (MTC) of samples used in the single-component efficacy evaluation experiment for improving intestinal colic and bloating (n = 30)

[0067]

[0068] As shown in the table above, the MTC of partially hydrolyzed proteins is greater than 12000 μg / mL; the MTC of docosahexaenoic acid is greater than 300 μg / mL. Subsequent dosing experiments will be designed based on the above MTC values.

[0069] Evaluation of the efficacy of the sample in improving colic

[0070] Three dfp wild-type AB strain zebrafish were randomly selected and placed in culture dishes. Except for the normal control group, all experimental groups were treated with TNBS dissolved in water to establish a zebrafish colic model. After treatment at 28℃ for 2 days, the TNBS was removed and the zebrafish were distributed into 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-dissolved samples (concentrations shown in Table 2) were used as examples / comparative examples, and prednisone 15.0 μg / mL was used as a positive control. A normal control group and a model control group were also set up, with a volume of 3 mL per well. After further treatment at 28℃ for 2 days, 10 zebrafish from each experimental group were randomly selected and placed in a 96-well plate. The total movement distance of the zebrafish was measured using a behavior analyzer, and the statistical analysis results of this index were used to evaluate the efficacy of the samples in improving colic. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software, and P < 0.05 was considered statistically significant. Then, for each embodiment and comparative example, the increase in total motion distance (mm) compared to the model control group was calculated (denoted as C), and for each embodiment, the sum of the increase in motion distance (mm) compared to the model control group for the corresponding comparative example was calculated (denoted as D). For example, for Example 1 (partially hydrolyzed protein concentration 750 μg / mL + docosahexaenoic acid concentration 50 μg / mL), the "sum of the increase in total motion distance compared to the model control group for the corresponding comparative example" is the sum of the "increase in total motion distance compared to the model control group" for Comparative Example 1 (partially hydrolyzed protein 750 μg / mL) and Comparative Example 5 (docosahexaenoic acid 50 μg / mL). Furthermore, based on the concentration of partially hydrolyzed protein (denoted as A) and the concentration of docosahexaenoic acid (denoted as B), the unit dose synergistic gain value (denoted as E, E=(CD) / (A+B)) was calculated. When E>0, it indicates the presence of a synergistic effect, and the larger the E value, the stronger the synergistic effect.

[0071] Following the above method, zebrafish were administered partially hydrolyzed protein and docosahexaenoic acid (DHA) at different ratios to evaluate their efficacy in improving intestinal colic. The dosages are shown in Table 2. The results are also shown in Table 2. Figure 1 As shown.

[0072] Table 2. Experimental results evaluating the efficacy of the samples in improving intestinal colic.

[0073]

[0074] Note: P indicates the significance level between the corresponding group and the model control group.

[0075] From Table 2, Figure 1 The results showed that, compared with the normal control group, the total movement distance of wild-type AB zebrafish induced by TNBS water-soluble administration in the model control group was significantly reduced (P < 0.001), indicating that the TNBS-induced intestinal colic model was successfully established. The positive control drug (prednisone), single-component partially hydrolyzed protein (3000 µg / mL, 12000 µg / mL), single-component docosahexaenoic acid (50 µg / mL, 150 µg / mL), and the drugs used in Examples 1-4 all significantly improved intestinal colic, specifically by significantly increasing the total movement distance compared with the model control (P < 0.05).

[0076] Example 1 (partially hydrolyzed protein to docosahexaenoic acid weight ratio of 15:1) is equivalent to a combination of Comparative Example 1 (single-component partially hydrolyzed protein 750 µg / mL) and Comparative Example 5 (single-component docosahexaenoic acid 50 µg / mL). Compared with the model control group, the increase in total movement distance in Example 1 was 2226 mm, while the increases in total movement distance in Comparative Examples 1 and 5 were 32 mm and 1527 mm, respectively. The former was greater than the sum of the latter two (1559 mm), indicating that Example 1 had a synergistic effect in improving intestinal colic. Similarly, Examples 2-4 also showed a synergistic effect in improving intestinal colic.

[0077] Furthermore, Examples 1-3 (with a weight ratio of partially hydrolyzed protein to docosahexaenoic acid of (5-180):1) showed a greater synergistic gain per unit dose compared to Example 4 (with a weight ratio of partially hydrolyzed protein to docosahexaenoic acid of 719:1), indicating that the synergistic effect of the two on improving intestinal colic was more significant at this weight ratio.

[0078] Furthermore, Examples 1-2 (with a weight ratio of partially hydrolyzed protein to docosahexaenoic acid of (5-15):1) showed a greater synergistic gain per unit dose compared to Examples 3-4 (with weight ratios of partially hydrolyzed protein to docosahexaenoic acid of 180:1 and 719:1, respectively), indicating that the synergistic effect of the two on improving intestinal colic was more significant at this weight ratio.

[0079] Evaluation of the efficacy of the sample in improving abdominal distension

[0080] Wild-type AB strain zebrafish (3 dpf) were randomly selected and placed in culture dishes. Except for the normal control group, all experimental groups were treated with TNBS dissolved in water. After treatment at 28℃ for 2 days, the TNBS was removed and the zebrafish were distributed into 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-dissolved samples (concentrations shown in Table 3) were used as examples / comparative examples, and prednisone 15.0 μg / mL was used as a positive control. A normal control group and a model control group were also set up, with a volume of 3 mL per well. After further treatment at 28℃ for 2 days, 10 zebrafish from each group were randomly selected, photographed under a dissecting microscope, and the images were saved. Data were collected using NIS-Elements D 3.20 advanced image processing software, and the intestinal lumen area of ​​the zebrafish was analyzed. The statistical analysis results of this index were used to evaluate the efficacy of the samples in improving abdominal distension in zebrafish. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS software; p < 0.05 indicated statistical significance. Then, for each embodiment / comparative example, the reduction in intestinal lumen area (pixels) compared to the model control group was calculated, and for each embodiment, the sum of the reductions in intestinal lumen area (pixels) of the corresponding embodiment compared to the model control group was calculated, and the unit dose synergistic gain value was calculated based on the concentration of partially hydrolyzed protein and the concentration of docosahexaenoic acid, as described above.

[0081] Following the above method, zebrafish were administered partially hydrolyzed protein and docosahexaenoic acid (DHA) at different ratios to evaluate their efficacy in improving abdominal distension. The dosages are shown in Table 3. The results are also shown in Table 3. Figure 2 As shown.

[0082] Table 3. Experimental results evaluating the efficacy of the samples in improving abdominal distension.

[0083]

[0084] Note: P indicates the significance level between the corresponding group and the model control group.

[0085] From Table 3, Figure 2 The results showed that, compared with the normal control group, the intestinal lumen area of ​​the 3 dpf wild-type AB zebrafish induced by TNBS water-soluble administration was significantly increased (P < 0.001). The positive control drug (prednisone), single-component partially hydrolyzed protein (3000 µg / mL, 12000 µg / mL), single-component docosahexaenoic acid (50 µg / mL, 150 µg / mL), and the drugs used in Examples 1-4 all significantly improved abdominal distension, specifically by significantly reducing the intestinal lumen area (in pixels) compared with the model control (P < 0.05).

[0086] Example 1 (partially hydrolyzed protein to docosahexaenoic acid weight ratio of 15:1) is equivalent to a combination of Comparative Example 1 (single-component partially hydrolyzed protein 750 µg / mL) and Comparative Example 5 (single-component docosahexaenoic acid 50 µg / mL). Compared with the model control group, Example 1 showed a reduction of 8817 pixels in intestinal lumen area (pixels), while Comparative Examples 1 and 5 showed reductions of 1919 pixels and 5875 pixels, respectively. The former is greater than the sum of the latter two (7794 pixels), indicating a synergistic effect of Example 1 in improving abdominal distension. Similarly, Examples 2-4 also showed a synergistic effect in improving abdominal distension.

[0087] Furthermore, Examples 1 and 3 (with a weight ratio of partially hydrolyzed protein to docosahexaenoic acid of (15-180):1) showed a greater synergistic gain per unit dose compared to Examples 2 and 4 (with weight ratios of partially hydrolyzed protein to docosahexaenoic acid of 5:1 and 719:1, respectively), indicating that the synergistic effect of the two on improving bloating was more significant at this weight ratio.

[0088] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of a nutritional composition in the preparation of a product for improving intestinal colic and / or bloating, wherein the nutritional composition comprises partially hydrolyzed protein and docosahexaenoic acid (DHA), wherein the partially hydrolyzed protein is selected from partially hydrolyzed whey protein, the degree of hydrolysis of the partially hydrolyzed protein is 10%-25%, and the weight ratio of the partially hydrolyzed protein to docosahexaenoic acid is (5-719):

1.

2. The use according to claim 1, wherein the product is used to improve intestinal colic and the weight ratio of the partially hydrolyzed protein to docosahexaenoic acid is (5-180):

1.

3. The use according to claim 1, wherein the product is used to improve bloating and the weight ratio of the partially hydrolyzed protein to docosahexaenoic acid is (15-180):

1.

4. The use according to claim 1, wherein the product is a medicine.

5. The use according to claim 1, characterized in that... The product contains 0.1% to 20% partially hydrolyzed protein and 0.01% to 0.5% docosahexaenoic acid, based on the total dry weight of the product.

6. The use according to claim 4, wherein the dosage form of the drug is selected from one or more of granules, powders, tablets, or liquids.

7. The use according to claim 1, wherein when taken orally in humans, the dosage of the partially hydrolyzed protein is 1-75 g / d, and the dosage of DHA is 0.03-1.5 g / d.

Images